Senate Health Committee advances PFAS restrictions, perinatal mental‑health requirements and additions to essential health benefits; several bills referred to ­

The Senate Committee on Health advanced a group of health‑policy measures on a busy agenda that ranged from a proposed class‑wide phaseout of PFAS chemicals to requirements for perinatal mental‑health screening and a process to update California's essential health benefits.

Senators and dozens of witnesses spent extended time over the three most contested bills: SB 682 (a class‑based approach to intentionally added PFAS in products), SB 626 (perinatal mental‑health screening, reporting and coverage), and SB 32 (developing time‑and‑distance standards for labor and delivery services). After testimony and amendment exchanges, committee members moved each measure forward to the fiscal committees or appropriations, where cost and implementation questions will be reviewed.

Why it matters: Committee action does not itself create statewide law, but advancing bills through policy committees is a key procedural step that lets authors negotiate cost and technical fixes in appropriations and fiscal hearings. The measures on PFAS, perinatal mental health and essential health benefits all touch large, statewide systems: consumer product supply chains, maternal health care delivery and the benefits covered by commercial plans sold in California.

PFAS regulation (SB 682)

Senator Ben Allen, the bill's author, described SB 682 as “a comprehensive and science based approach to phasing out unnecessary uses of PFAS that is intentionally added to products.” He told the committee the bill would prohibit the sale or distribution of products with intentionally added PFAS beginning on set timelines unless the Department of Toxic Substances Control (DTSC) grants an unavoidable‑use exemption based on three criteria: no safer alternative, a needed function, and that the product is necessary for public health, safety or societal functioning. The bill includes longer timelines and separate treatment for complex industrial uses such as certain semiconductors and fluorinated gases.

Dr. Anna Reed, identified as director of PFAS science and policy at the Natural Resources Defense Council, urged a "class‑based" approach and said exposure is widespread and harmful. "All PFAS are extremely persistent or transform into extremely persistent PFAS, lasting for hundreds to thousands of years," she told the committee. Dr. Max (a professor at USC testifying as an individual researcher) summarized epidemiologic findings linking PFAS exposure to multiple health outcomes and urged measures to reduce future avoidable use.

Supporters included municipal and water agencies and environmental and public‑health groups; opponents included trade groups representing life‑sciences, manufacturing, and industry sectors. The California Life Sciences Association, speaking in opposition, warned the bill could disrupt medical device and pharmaceutical supply chains and said the current draft left ambiguity about whether upstream components are covered. The Chamber and industry groups raised broader economic and procedural concerns, particularly about concentrating many technical determinations in a single state agency.

Committee action: The author accepted committee amendments on the record. The committee subsequently moved the bill out of policy and referred it to the appropriations process for fiscal review.

Perinatal mental health (SB 626)

Senator Susan Rubio (author) described SB 626 as a measure to require standardized screening, diagnosis and treatment pathways for perinatal mood and anxiety disorders in line with American College of Obstetricians and Gynecologists guidance, and to require insurer coverage of at least one FDA‑approved medication and one FDA‑cleared digital therapeutic for perinatal mental health. Rubio said perinatal mental‑health conditions are common and an under‑detected contributor to maternal mortality.

Dr. Saurabh Kumar, an OBGYN who testified as a clinician and former editor for ACOG, told the committee clinicians often avoid screening and treatment because of coverage uncertainty. He said having on‑label options and insurer reporting requirements would reduce barriers, speed treatment, and create data for future refinements. Patient advocates and community groups also testified; legislators described lived‑experience testimony in the hearing as a key impetus.

Insurers and plan associations raised concerns about potential cost and the particulars of coverage mandates but did not enter formal opposition after the committee amendments discussed limiting the bill to currently available FDA‑cleared products and adding reporting elements.

Committee action: SB 626 was moved out of committee as amended and referred to appropriations for fiscal and implementation review.

Updates to essential health benefits (SB 62)

Senator Menjivar led a special‑order discussion of SB 62, a bill to codify additions to California's essential health benefits (EHB) benchmark that the Department of Managed Health Care (DMHC) has proposed for federal submission. The package discussed by the committee would add three categories to California's benchmark if approved by the Centers for Medicare & Medicaid Services (CMS): routine hearing screenings and hearing aids (every three years), specified durable medical equipment (wheelchairs, oxygen and personal mobility devices), and coverage for infertility diagnosis and treatment including in vitro fertilization (subject to federal approval of the benchmark).

Mary Wachenhoff (identified as the DMHC director in the hearing) told the committee DMHC released a draft submission to CMS and planned a final filing by the agency's May deadline; the statute would codify the benefits if CMS approves the state benchmark. Wachenhoff noted the process allows California to withdraw or adjust its application before the federal approval if needed. Advocates testified in strong support, emphasizing access and equity benefits; some plans expressed concern about timing and potential premium impacts, urging coordination with federal subsidy changes.

Committee action: The committee advanced SB 62 and referred it to appropriations with the author and agency continuing a dialogue about timing and implementation if CMS approves the benchmark.

Medigap access reforms (SB 242)

Senator announced SB 242, a proposal to change how Medigap (Medicare supplemental) policies are offered and to create guaranteed‑issue opportunities for older adults and people with end‑stage renal disease. Supporters — patient advocates, hospital systems and disease organizations — argued that the measure would prevent people from being locked into Medicare Advantage plans when provider networks change and ensure access to lifesaving care. Opponents — trade groups representing insurers and agents — warned of adverse selection and large premium increases, citing estimates that changes could materially raise per‑member premiums and lead some carriers to withdraw or consolidate.

Committee action: The author took committee amendments addressing rate‑banding and protections for existing enrollees and agreed to continue working with stakeholders; the measure was moved to appropriations for further fiscal analysis.

Youth drop‑in centers billing (SB 812)

SB 812 would allow youth drop‑in centers designated or embedded by local schools or colleges to bill under the Children and Youth Behavioral Health Initiative (CYBHI) fee schedule, creating a more sustainable billing pathway for youth drop‑in centers that serve students and disconnected youth. Sponsors and youth leaders testified that the centers provide low‑barrier, confidential services and that billing through the fee schedule would stabilize funding. DMHC and health‑plan representatives asked for clarity about continuity of care, referral and contractual requirements; the author accepted committee amendments tying fee‑schedule access to formal school contracts and referral procedures to preserve care coordination.

Committee action: SB 812 moved forward to appropriations.

Freestanding emergency departments study (SB 588)

Senator presented SB 588, a request that the state's Health Care Access and Information office (HCAI) study the feasibility of freestanding emergency departments (FEDs) in rural, disadvantaged and underserved areas, examining operational models, economic viability, regulatory barriers and community impacts. Supporters — including emergency physicians and rural hospital leaders — argued the study would evaluate options to provide stabilization and transfer capability closer to remote populations. Opponents — labor unions, nursing groups and emergency medicine societies — raised long‑standing concerns about FEDs: risk of fragmenting care, high out‑of‑pocket costs for patients, and the potential for FEDs to siphon higher‑paying patients away from financially fragile community hospitals.

Committee action: The author accepted the chair's suggestion to make SB 588 a two‑year bill and to continue stakeholder work rather than pressing the study this session.

What the committee did procedurally

Across the hearing the committee accepted multiple author amendments, heard detailed technical testimony from state agencies (including DMHC and the Department of Toxic Substances Control themes in the PFAS debate), and advanced each listed measure from policy into fiscal review. Several measures were moved "as amended" and referred to the appropriations/fiscal committees for cost analysis and possible budgetary changes before they can reach the floor.

Closing note

Committee members repeatedly emphasized that advancing a bill through policy does not implement it statewide; it opens a multi‑step negotiation with fiscal committees, state agencies and stakeholders where technical fixes, funding sources and timeline changes are worked out. Several chairs urged additional stakeholder meetings, clarified that federal approvals (for EHB changes and other items) can alter timing, and stressed that the committee would continue to work with authors to refine language and address implementation concerns.

Ending

All committee actions reported at the hearing are subject to the next legislative steps — fiscal committee review, possible floor votes, and, if passed by both houses, gubernatorial action. The bills moved at this hearing remain active but will undergo further amendment and fiscal scrutiny before becoming law.